- Home
- » Tags
- » Epratuzumab
Top View
- (ESGICH) Consensus Document on the Safety of Targeted And
- Stembook 2018.Pdf
- Recent Biotherapies and Infections
- Contents Volume 73 Issue 1 | ARD January 2014 Editorial Viewpoint
- (INN) for Biological and Biotechnological Substances
- In Primary Sjögren's Syndrome
- Biosimilar Antibodies & ELISA Kits
- Belimumab Treatment for Adults with Systemic Lupus Erythematosus: a Review of Clinical Effectiveness, Cost- Effectiveness, and Guidelines
- July 2017 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
- Development of Therapeutic Antibody Technology and Recent
- Targeting B Cells to Treat Systemic Lupus Erythematosus
- Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
- Long‐Term Safety and Efficacy of Epratuzumab in The
- B-Cell-Targeted Therapies in Systemic Lupus Erythematosus
- Wo 2010/095940 A2
- New Antibody Approaches to Lymphoma Therapy Tejas Suresh1, Lisa X Lee1, Jitesh Joshi1 and Stefan K Barta2*
- Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: an Overview
- Antibody Purification by Cation Exchange Chromatography
- Chapter 2 Technetium in Medicine 2
- Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens
- Anti-CD22 Igg) in B-Cell Malignancies
- Epratuzumab–SN-38: a New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies
- Immunotherapy of Lymphomas
- Customs Tariff - Schedule Xxi - 1
- Immunotherapy – a Novel Facet of Modern Therapeutics Immunotherapy – a Novel Facet of Modern Therapeutics Sujata P
- Biosimilar Antibodies and ELISA Kits
- Belimumab May Be First Biologic Okayed for SLE
- Correspondence to 'Time to Change the Primary Outcome of Lupus Trials'
- Reports from the Targeted Therapies Meeting 2019
- Oral Presentations
- What's on the Horizon with Lupus Clinical Trials?: an Overview
- W W W .Bio Visio N .Co M
- October 2017 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
- Biologic Therapies in Patients with Neuropsychiatric Systemic Lupus
- Review Article the Biological Disease-Modifying Antirheumatic Drugs and the Risk of Cardiovascular Events: a Systematic Review and Meta- Analysis
- Anti-CD22 90Y-Epratuzumab Tetraxetan
- Immuno-Intervention: Perspectives Thérapeutiques
- Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
- Understanding Non-Hodgkin Lymphoma a Guide for Patients, Survivors, and Loved Ones
- Nhs-England-Drugs-List-V14.1.Pdf
- Biologic Therapy for Autoimmune Diseases: an Update Ziv Rosman1, Yehuda Shoenfeld2,3 and Gisele Zandman-Goddard1,3*
- Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
- (INN) for Biological and Biotechnological Substances
- January 2018 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
- + Rituximab in Previously Untreated Follicular Non-Hodgkin’S Lymphoma: CALGB 50701 Bruce D
- Biosimilar Monoclonalantibodies
- (12) United States Patent (10) Patent No.: US 8,968,730 B2 Koenig Et Al
- Assessment of the Evolution of Cancer Treatment Therapies
- UCB R&D Days
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Rheumatology & Therapeutics
- Anti‑CD22 Epratuzumab for Systemic Lupus Erythematosus: a Systematic Review and Meta‑Analysis of Randomized Controlled Trials